Internis Pharmaceuticals
London, England, United Kingdom
About Internis Pharmaceuticals
Internis is an exciting and innovative British start-up business. Founded in 2010, it is a pharmaceutical company engaged in the development and commercialisation of highly effective and innovative new medicines aimed at the treatment and prevention of a range of common bone disorders, such as osteoporosis and vitamin D3 deficiency. Internis supplies a prescription only licensed medicine (FultiumD3) to treat patients with a vitamin D deficiency. Vitamin D is offered to at-risk groups on prescription to prevent the health risks associated with a deficiency or insufficiency. It is estimated that up to a quarter of the population in the UK have low levels of vitamin D in their blood – with deficiency linked to conditions including bone deformities and health complications such as depression, joint pain, migraines, fatigue and a weakened immune system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $3.1M
- Funding stage: M&A
- Last round: Debt Financing (Sep 2013)
- Website: internisvitd3.com
- Phone: +44 20 8349 5422
Industries & Categories
Health Care, Manufacturing, Medical Device, Pharmaceutical
Canonical: https://fsome.com/organization/internis-pharmaceuticals-2491157 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.